Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Glycogen storage disorders GSD are inherited metabolic diseases affecting glycogen production or breakdown, mainly involving the liver and muscles. These disorders vary in severity from mild to fatal in infancy. This study focuses on hepatic GSD types 0a, I, III, IV, VI, IX, and XI in Indian children. It aims to establish a comprehensive Indian GSD registry to better understand the spectrum of genetic defects, natural progression, and how genetic variations relate to disease symptoms in this population. The study is a multicenter observational effort collecting both retrospective and ongoing prospective data from genetically confirmed pediatric hepatic GSD cases. It involves analyzing clinical presentations, outcomes, and genetic variations across multiple centers in India. Retrospective data collection and analysis are planned between May 2024 and April 2025, with continued data submission from new centers and periodic follow-up every 6 months to 1 year. The registry will help guide individualized treatment decisions, including medical therapy or liver transplantation. Participants are children diagnosed genetically with hepatic GSD. The research team reviews clinical data, genetic testing results, and long-term outcomes such as native liver survival and post-transplant complications. The study measures the association between specific gene variants and clinical disease expression over a 5-year period. This ongoing project aims to improve understanding of GSD in Indian children to support better diagnosis, management, and health policies.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of adding KarXT to existing treatments for mania in adults with Bipolar-I Disorder. This trial focuses on participants experiencing an acute manic episode, with or without mixed features, who are already taking lithium, valproate, or lamotrigine. The study aims to improve mania symptoms, measured by changes in the Young Mania Rating Scale after five weeks. Participants will be randomly assigned to receive either KarXT in addition to their mood stabilizer or a placebo plus their mood stabilizer. The treatments are given in specified doses over the study period, with careful monitoring of side effects and other health measures. The study includes a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants will undergo regular assessments including psychiatric evaluations, rating scales for mania and other symptoms, and safety monitoring up to seven weeks. Researchers will track symptom changes, treatment responses, and any adverse events. Participants are involved in scheduled visits for evaluations and to maintain stable mood stabilizer doses. The total participation lasts until the primary outcome is measured at week five, with additional safety follow-up up to week seven.
Actively Recruiting
Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.
Actively Recruiting
Researchers are evaluating the safety and tolerability of rimegepant 75 mg orally disintegrating tablet ODT for the acute treatment of migraine, with or without aura, in adult patients in India who have previously had an insufficient response, intolerance, or contraindications to triptans. This is a multicenter, single-arm, open-label Phase 4 study enrolling approximately 60 participants to better understand the safety profile of rimegepant in this population. Participants who qualify will be enrolled within 28 days after screening. Each participant will receive a single blister card containing one 75 mg ODT tablet of rimegepant to be taken as needed during a migraine attack within 30 days of the baseline visit. After taking the medication, participants must notify the study site by phone within 12 hours, and then will receive a follow-up phone call about 2 days later to assess any adverse events or side effects. Participant satisfaction with the medication will also be evaluated during this call. Finally, participants will attend an end-of-study visit 28 to 35 days after dosing. Participation lasts up to 93 days, including up to 28 days for screening, a 30-day treatment window, and up to 35 days of follow-up after dosing. During the study, safety is monitored through phone calls and the end-of-study visit. Researchers will measure treatment-emergent adverse events, serious adverse events, vital sign abnormalities, and participant satisfaction using a specific questionnaire. This careful monitoring aims to gather detailed information on the use of rimegepant for migraine treatment in adults in India.
Actively Recruiting
Phase 3 Study of Rimegepant for Intermittent Prevention of Menstrual Migraine in Women Aged 18 to 45
Researchers are evaluating the use of rimegepant for intermittent prevention of menstrual migraine in women aged 18 to 45 who experience migraine attacks related to their menstrual cycle. This Phase 3, double-blind, randomized study compares rimegepant with placebo to assess its efficacy and safety during the peri-menstrual period. The study focuses on migraine frequency and severity in women with a history of menstrual migraine and regular menstrual cycles. Participants receive either rimegepant 75 mg orally disintegrating tablets for 7 days during each peri-menstrual period or a matching placebo, along with standard care for acute migraine treatment as needed. The study treatment cycles are repeated over 5 menstrual cycles in the double-blind treatment phase. The study also includes an acute treatment dosing option with rimegepant as needed. During the study, participants will be monitored for changes in the number of migraine and headache days, use of migraine medications, and functional disability related to migraine. Cognitive function is also assessed. Researchers will conduct evaluations over 5 months, covering 5 menstrual cycles, and measure outcomes related to migraine frequency and severity during the peri-menstrual period. Safety and tolerability will be closely monitored throughout the study.
Actively Recruiting
Hypoxic-ischemic encephalopathy HIE is a serious brain condition in newborns caused by lack of oxygen and blood flow around the time of birth. This condition can lead to severe brain injury and long-term disabilities. Researchers are studying the use of sovateltide, a drug that targets brain cell receptors to support nerve cell growth and repair, as a new treatment option for neonates with HIE. Current treatments like therapeutic hypothermia have limited success and must be started quickly after birth, highlighting the need for additional therapies. In this phase II clinical trial, newborns with HIE will receive either sovateltide plus standard care or a placebo normal saline plus standard care. The sovateltide or placebo will be given intravenously in a bolus dose every 3 hours on days 1, 3, and 6 after randomization. Both groups will also receive the best available supportive treatments for perinatal asphyxia. Participants will be monitored over 24 months for outcomes such as death or moderate to severe disability, brain injury, seizures, cerebral palsy, blindness or hearing loss, and overall developmental progress using standardized assessments. Safety and tolerance of the treatment will be evaluated, with follow-up visits including clinical evaluations and neurological assessments. The study aims to determine if sovateltide can improve neurological outcomes and survival in newborns affected by HIE.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a new oral cladribine formulation in adults with Generalized Myasthenia Gravis gMG. This Phase 3 clinical trial compares two doses of cladribine with a placebo and also studies the long-term safety, sustained effects, and need for retreatment of cladribine in people with gMG. Additionally, the study will examine how the body processes cladribine through a pharmacokinetic sub-study. Participants are randomly assigned to one of three groups placebo, low dose cladribine, or high dose cladribine. Each group receives two separate treatment courses orally, starting on Day 1 and again at Week 5 during the double-blind placebo-controlled period. After this, participants enter a blinded extension where those initially on placebo switch to cladribine doses, and those initially on cladribine receive placebo courses. If needed, participants may enter a retreatment period to receive additional cladribine or placebo doses based on clinical judgment. During the study, participants undergo regular assessments including changes in muscle weakness and daily living activities using specific scales like the MG-ADL. Safety is monitored through tracking adverse events, lab tests, vital signs, and heart monitoring. The study also includes in-depth interviews with a subset of participants to understand their treatment and study experience. The total study duration extends up to 144 weeks, allowing long-term follow-up and evaluation.
Actively Recruiting
Healthy Volunteer
Researchers are investigating biomarkers and host factors linked to dengue severity in patients from regions where dengue is common. The study aims to determine if multi-omics techniques can predict disease severity and identify key factors involved in severe dengue infections. This observational research focuses on understanding how dengue virus manipulates host metabolism and immune responses to better predict disease progression and find new treatment targets. Participants include individuals with dengue infection classified by severity dengue without warning signs, dengue with warning signs, severe dengue, and a group of healthy controls. Blood samples will be collected at hospitalization and discharge and analyzed using transcriptomics, proteomics, and metabolomics. The study includes discovery cohorts from Guatemala and validation cohorts from India, aiming to explore viral serotypes, host cytokine profiles, and cellular pathways involved in disease severity. During the study, participants will provide blood samples for detailed laboratory analysis. Researchers will measure biomarkers to understand immune responses and disease mechanisms. The primary outcome is discovering predictive biomarkers and developing an AI tool for dengue severity, monitored from enrollment until two weeks after hospitalization. The study also involves matching controls for age and gender, with careful screening to exclude recent dengue infections.
1-10 of 15
1